Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech

Summary

Scribe Therapeutics, founded by Jennifer Doudna, raised approximately $129M in an IPO—the first gene editing biotech public offering in over two years. The company plans to use proceeds to advance its epigenetic silencing therapy for atherosclerotic cardiovascular disease.